Hypoprothrombinemia in Patients With Cancer Receiving Cefoperazone and Mezlocillin

Paula G. Jones, S. Vance Strother, Kenneth V.I. Rolston, Victor Fainstein, Gerald P. Bodey

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

• Forty-one patients with cancer who were receiving cefoperazone sodium plus mezlocillin sodium were prospectively followed up for the development of abnormal bleeding or hypoprothrombinemia. Ten of 41 patients developed an increased prothrombin time, three with a hemorrhagic episode. Serum transport proteins and serum carotene were measured in 18 patients, six of whom developed hypoprothrombinemia. Low serum prealbumin and low serum carotene levels were associated with the development of hypoprothrombinemia. Patients with cancer are especially predisposed to the development of antibiotic-associated hypoprothrombinemia. This is probably a result of protein-calorie malnutrition and low vitamin K stores.

Original languageEnglish (US)
Pages (from-to)1397-1399
Number of pages3
JournalArchives of Internal Medicine
Volume146
Issue number7
DOIs
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Hypoprothrombinemia in Patients With Cancer Receiving Cefoperazone and Mezlocillin'. Together they form a unique fingerprint.

Cite this